Project cooperationUpdated on 18 June 2025
Microgravity-Enabled Organ-on-Chip: Seeking Pharma/Biotech Co-Development Partners
About
CeleroSpace is pioneering a modular, microgravity-ready platform for advanced Organ-on-Chip (OoC) research beyond Earth. We are actively seeking pharmaceutical and biotech partners to co-develop or validate OoC models in microgravity, leveraging unique physiological advantages such as enhanced cell differentiation, reduced shear stress, and novel 3D tissue formation observed in space.
Microgravity provides a transformative environment to accelerate discovery of disease mechanisms, drug toxicity, and cell response—all with increased biological relevance. With commercial reentry capsules and space stations becoming more accessible, our mission is to democratize microgravity R&D for therapeutic innovation.
Our plug-and-play system will be design to support modular biosensor integration and is designed with pharma standards and MDR alignment in mind. Early collaboration offers partners exclusive access to the development cycle, joint IP opportunities, and customized validation scenarios.
Let’s reshape drug development—starting from orbit.
Stage
- Early
Type
- Research
- Technical
- Financing
Organisation
Similar opportunities
Product
NeoMag: Revolutionize your research with accurate biomechanical modeling
- Other
- Distribution Partner
- Laboratory industry
- Pharmaceutical industry
Ricardo de la Torre
CEO at 60Nd
Madrid, Spain
Service
Clinical Trial Supply & Logistics Services
- Development
- Manufacturing
- Pharmaceutical industry
Marc Brehme
Founder & Managing Director at M-B-V-C
Vienna, Austria
Service
Precision Oncology and Antitumour Therapies
Raquel Rodriguez
Technology Transfer and Innovation Promotion Specialist at Universidad de Alcalá
Alcalá de Henares, Spain